About US
Contact us
-
Apellis Pharma and its rare disease, eyecare drugs draw takeover interest: BloombergAmid a recent streak of rare disease M&A deals in the biopharma industry, Apellis has attracted takeover interest, Bloomberg reports. The rare diseases and ophthalmology specialist is2023/4/4
-
After Johnson & Johnson loses again in bankruptcy case, it's game on for talc lawsuitsAfter Johnson & Johnson’s initial victory in its attempt to resolve talc lawsuits through a bankruptcy ploy, little has gone the way of the pharma giant. Friday, J&J took another2023/4/4
-
In $2.6B cell and gene therapy expansion, Sartorius buys viral vector specialist PolyplusAs the biopharma industry struggles with a dire shortage of viral vectors to make cell and gene therapies, contract manufacturers are busy beefing up their capabilities. In the latest exa2023/3/31
-
Biogen comes out ahead in investor lawsuit over Aduhelm disclosuresBiogen hasn’t had many wins with its failed Alzheimer’s disease drug Aduhelm, but now the company can chalk up a courtroom victory. This week, aMassachusetts federal judge dismissed an in2023/3/31
-
After Amarin's clash with Sarissa, CEO Karim Mikhail hits the exitIn the wake of a fight over board control with activist investor group Sarissa Capital, Amarin's CEO Karim Mikhail has abruptly left the drugmaker. Friday, in a SEC filing, AmarinsaidMikhail resigned2023/3/29
-
Fierce Pharma Asia—Takeda's manufacturing expansion; Leqembi's sales prospects; GSK's PrEP genericsTakeda is investing heavily in plasma-derived therapies. GlobalData expects Eisai and Biogen's Leqembi to accumulate $12.9 billion in sales through 2028.Viatris, Cipla and Aurobindo will make generic2023/3/29
-
Muscular Dystrophy Association and Burn Boot Camp to raise money with national workoutBurn Boot Camp, a boutique fitness franchise, joined with the Muscular Dystrophy Association (MDA) and 2023 MDA National Spokesperson Buffalo Bills running back Nyheim Hines to remind people that wor2023/3/27
-
Bipartisan caucus in US Congress looks to boost domestic drug manufacturingFour members of the U.S. House of Representatives haveformed a bipartisan groupdubbed the Domestic Pharmaceutical Manufacturing Caucus for the 118th Congress. The group will focus on domestic product2023/3/27
-
Viatris, Cipla and Aurobindo sign up to make generics of GSK's long-acting HIV PrEP drugIn an effort to bolster drug access in dozens of countries around the globe, three generics makers have obtained sublicenses to make low-cost versions of GSK’s long-acting HIV PrEP drug Apretude.2023/3/22
-
Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026: Moody'sDrug price negotiation is the boogeyman awaiting Big Pharma in 2026. So, which medicines will be subject to the U.S. government’s newfound ability to broker prices—the mostimpactfulmeasure from last2023/3/22